Stock Market Update - July 8, 2026
Today's stock market saw some significant movers. Here's a breakdown of 3 stocks that caught our attention:
1. VTAK - Catheter Precision, Inc.
Price: $1.37 | Change: +92.23% ($0.6573)
VTAK soared with an impressive 92.23% gain around July 9, 2026, driven by a flurry of positive developments across its different business segments. Catheter Precision, the company behind VTAK, announced two new patents: one for enhancing precise cardiac arrhythmia identification and another for improving its heart failure neuromodulation technology by reducing signal noise.
Adding to the momentum, its regional air mobility subsidiary, Flyte, reported significant operational milestones. Flyte surpassed 1,000 users, completed 118 flights, and generated over $1 million in revenue for 2026, demonstrating strong quarter-over-quarter growth. Flyte also formed a safety partnership with LifeVac, acquired a 7.5% stake in Volato (SOAR) to become its largest shareholder, and launched a marketing partnership with PGA TOUR golfer Emiliano Grillo.
What makes VTAK's surge particularly interesting is the diverse nature of these catalysts, spanning both cutting-edge medical devices and rapid expansion in the private air travel market. This combination of innovation and strategic growth fueled strong investor optimism.
2. NVVE - Nuvve Holding Corp.
Price: $8.49 | Change: +63.58% ($3.3)
NVVE saw a 63.58% gain, but this eye-catching jump wasn't driven by a sudden surge in demand or new business deals. Instead, it was primarily a direct result of a 1-for-18 reverse stock split that Nuvve Holding Corp. implemented in early July 2026.
This corporate action, which saw every 18 existing shares converted into one new share, was primarily aimed at helping Nuvve meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing. By significantly reducing the number of outstanding shares, the per-share price was proportionally adjusted upward. It's crucial to note that this kind of price increase is generally considered "artificial" as it doesn't reflect a fundamental improvement in the company's financial health or market capitalization, but rather a change in its share structure.
3. TVRD - Tvardi Therapeutics, Inc.
Price: $5 | Change: +61.29% ($1.9)
TVRD surged an impressive 61.29% after Tvardi Therapeutics announced exciting positive Phase 1 clinical trial results for its drug, TTI-109, on July 7, 2026. This significant jump in stock price reflects strong investor enthusiasm for the company's next-generation treatment.
The key takeaway from the study was TTI-109's improved tolerability. Compared to an earlier version, it dramatically reduced gastrointestinal side effects like diarrhea, making it a much more patient-friendly option. Importantly, the trial also confirmed that the drug effectively engaged its target, showing a reduction in specific immune cells linked to disease.
These favorable outcomes are a big win for Tvardi's drug pipeline. The company now plans to advance TTI-109 into Phase 2 trials for various skin and gastrointestinal conditions. This progress, along with an analyst upgrade from Raymond James, underscores the growing confidence in Tvardi's potential.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.